Sentences with phrase «cancer drug discovery research»

Not exact matches

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

Looking at sixty - seven recent drug discovery projects based on preclinical cancer biology research, they found that in more than 75 percent of cases the published data did not match up with their in - house attempts to replicate.

Research like this, that's made publically available, will help speed up crucial advances in drug discovery to save more lives from cancer.»

One of the most exciting recent advances in clinical cancer research was the discovery that this subgroup of patients respond — sometimes dramatically — to a new class of drugs targeting the MAPK pathway through which BRAF signals.

There are currently 25 research groups in our school and areas of research in Biochemistry include membrane proteins, enzymology, folic acid biochemistry, structural biology, tRNA biology, neurochemistry, neurodegeneration, metabolism, systems biology, cancer biology, molecular parasitology, apoptosis and drug discovery.

Christophe Quéva, chief scientific officer, commented «The building of a custom designed R&D facility demonstrates our commitment to our cancer immunology research programs and will enable us to recruit additional qualified scientists needed in both our drug discovery and development.»

MD Anderson's Institute for Applied Cancer Science (IACS) in combination with Deerfield will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.

Career Goals: I plan to pursue a career in scientific research focusing on the discovery of drug targets to improve the treatment options of human immunological diseases and cancer.

The discovery builds on research showing that a promising class of new drugs for BRCA2 linked breast cancers — known as PARP inhibitors ** — may also be effective in men who have developed prostate cancer due to a BRCA2 alteration.

Topics covered include embryonic stem cells, pluripotency, germline stem cells, tissue - specific stem cells, stem cell differentiation, epigenetics, stem cell genomics and systems biology, genome reprogramming, cancer stem cells, stem cell niches, stem - cell - based disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging of stem cells, therapeutic applications, regenerative medicine, clinical and translational insights, stem cell research policies, ethical issues, and technical or resource - based innovations.

Some of the pediatric research conducted in a new building to be built on the Emory campus will focus on cardiology, cancer, vaccines, and new drug discovery.

Dr Iain Foulkes, Cancer Research Technology's CEO, said: «This bold and exciting collaboration between one of industry's leading innovators, Celgene, and CRT is part of our theme - based drug discovery approach and helps leverage our understanding of cancer biology and the needs of patients to drive the most promising discoveries into the cCancer Research Technology's CEO, said: «This bold and exciting collaboration between one of industry's leading innovators, Celgene, and CRT is part of our theme - based drug discovery approach and helps leverage our understanding of cancer biology and the needs of patients to drive the most promising discoveries into the ccancer biology and the needs of patients to drive the most promising discoveries into the clinic.

Cancer Research Technology will lead drug discovery R&D activity and can progress clinical candidates through phase one trials.

Despite ongoing efforts toward finding novel entities for the treatment of the most challenging cancers, translation into patient benefit has been slow due to the fact that translational cancer research from early drug discovery to late stage drug development and assessment in clinical trials is a long process.

Pharmaceutical research scientist with 34 years of experience in the area of oncology, twenty - five of them doing drug discovery research in the Cancer Department at Merck Researresearch scientist with 34 years of experience in the area of oncology, twenty - five of them doing drug discovery research in the Cancer Department at Merck Researresearch in the Cancer Department at Merck ResearchResearch Labs.